US Drug Recall Register

FDA Drug Recalls

11,815 recalls · Class II, newest first

Risk Class IClass IIClass III
Status OngoingCompletedTerminated
Year 2026202520242023
Class II · Moderate risk Terminated

Simvastatin Tablets USP 20 mg Rx Only

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-005-15 D-0410-2023
Class II · Moderate risk Terminated

Simvastatin Tablets

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-004-15 D-0409-2023
Class II · Moderate risk Terminated

Simvastatin Tablets USP 5 mg Rx Only

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-156-15 D-0408-2023
Class II · Moderate risk Terminated

Rosuvastatin Tablets

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-287-10 D-0407-2023
Class II · Moderate risk Terminated

Rosuvastatin Tablets

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-286-15 D-0406-2023
Class II · Moderate risk Terminated

Rosuvastatin Tablets

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-285-15 D-0405-2023
Class II · Moderate risk Terminated

Rosuvastatin Tablets

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-284-15 D-0404-2023
Class II · Moderate risk Terminated

Phenylephrine Hydrochloride Injection

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-466-03 D-0403-2023
Class II · Moderate risk Terminated

Phenylephrine Hydrochloride Injection

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-465-31 D-0402-2023
Class II · Moderate risk Terminated

Phenylephrine Hydrochloride Injection

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-464-63 D-0401-2023
Class II · Moderate risk Terminated

Montelukast Sodium Tablets

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-119-10 D-0400-2023
Class II · Moderate risk Terminated

Glycopyrrolate Injection

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-474-05 D-0399-2023
Class II · Moderate risk Terminated

Glycopyrrolate Injection

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-473-31 D-0398-2023
Class II · Moderate risk Terminated

Glycopyrrolate Injection

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-472-30 D-0397-2023
Class II · Moderate risk Terminated

Glycopyrrolate Injection

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-471-63 D-0396-2023
Class II · Moderate risk Terminated

Glimepiride Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-003-01 D-0395-2023
Class II · Moderate risk Terminated

Glimepiride Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-002-01 D-0394-2023
Class II · Moderate risk Terminated

Glimepiride Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-001-01 D-0393-2023
Class II · Moderate risk Terminated

Finasteride Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-090-10 D-0392-2023
Class II · Moderate risk Terminated

Finasteride Tablets USP 1 mg

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 71713-096-90 D-0391-2023
Class II · Moderate risk Terminated

Finasteride Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-089-10 D-0390-2023
Class II · Moderate risk Terminated

Doxazosin Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-415-01 D-0389-2023
Class II · Moderate risk Terminated

Doxazosin Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-213-01 D-0388-2023
Class II · Moderate risk Terminated

Doxazosin Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-414-01 D-0387-2023
Class II · Moderate risk Terminated

Doxazosin Tablets USP 1 mg

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-211-01 D-0386-2023